Actively Recruiting

Age: 18Years - 90Years
All Genders
ID06169163

Volatile Organic Compounds as Breath Biomarkers in Squamous Oesophageal Neoplasms

Led by Imperial College London · Updated on 2025-05-02

518

Participants Needed

13

Research Sites

4 weeks

Total Duration

On this page

Sponsors

I

Imperial College London

Lead Sponsor

I

Imperial College Healthcare NHS Trust

Collaborating Sponsor

AI-Summary

What this Trial Is About

Oesophageal Squamous Cell Carcinoma (OSCC) is a type of cancer affecting the food pipe, with poor survival rates when detected late. Early detection greatly improves survival, but current methods like endoscopy are invasive and uncomfortable. Researchers are evaluating a breath test that detects volatile organic compounds produced by the cancer, aiming to offer a non-invasive, simple, and cost-effective way to identify OSCC early in patients with non-specific symptoms. This study involves two groups: one with patients newly diagnosed with OSCC who have not yet received treatment, and a control group undergoing endoscopy for upper gastrointestinal symptoms but without cancer. Participants will provide breath samples by exhaling into single-use collection bags twice, with the samples then analyzed at a laboratory to identify cancer-related compounds. Room air samples will also be collected for comparison. Participants will be asked to provide breath samples after maintaining a clear fluid diet for at least six hours. The study will measure the accuracy of the breath test in detecting OSCC and assess factors that might affect the test results. The total study duration for outcome measurement is 36 months, supported by multiple centers and led by Imperial College London.

CONDITIONS

Brief Title

Volatile Organic Compounds as Breath Biomarkers in Squamous Oesophageal Neoplasms

Who Can Participate

Age: 18Years - 90Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with treatment naive, histopathology confirmed oesophageal squamous cell carcinoma
  • Patients undergoing or having undergone upper gastrointestinal endoscopy for symptoms
  • Control patients with normal upper gastrointestinal tract or benign upper gastrointestinal disease
  • Age between 18 and 90 years
  • Ability to provide written consent
Not Eligible

You will not qualify if you...

  • Received treatment for oesophageal squamous cell carcinoma (chemotherapy, radiotherapy, immunotherapy, endoscopic resection, or surgery)
  • History of another cancer in the last five years
  • Non-squamous cell oesophageal cancer
  • Barrett's oesophagus with or without dysplasia
  • Previous oesophageal or gastric surgery
  • Unable to provide written consent or lacking capacity
  • Pregnant women

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - 1 day

Participants provide breath samples by exhaling into single-use breath collection bags. This includes transferring volatile organic compounds onto thermal desorption tubes for later analysis.

1 visit (in-person)

Long-term Monitoring

Duration - Up to 36 months

Participants are observed over time to evaluate the presence of breath biomarkers related to oesophageal squamous cell carcinoma and effects of confounding variables.

No additional visits required

Trial Site Locations

Total: 13 locations

1

Imperial College Healthcare NHS Trust

London, Greater London, United Kingdom, W12 0NN

Actively Recruiting

2

Hull University Teaching Hospitals NHS Trust

Cottingham, Hull, United Kingdom

Actively Recruiting

3

Cardiff and Vale University Health Board

Cardiff, United Kingdom

Not Yet Recruiting

4

Velindre NHS Trust

Cardiff, United Kingdom

Not Yet Recruiting

5

University Hospitals Coventry and Warwickshire NHS Trust

Coventry, United Kingdom

Actively Recruiting

6

University Hospitals of Leicester NHS Foundation Trust

Leicester, United Kingdom

Actively Recruiting

7

Liverpool University Hospitals NHS Foundation Trust

Liverpool, United Kingdom

Not Yet Recruiting

8

The Clatterbridge Cancer Centre NHS Foundation Trust

Liverpool, United Kingdom

Actively Recruiting

9

Bedfordshire Hospitals NHS Foundation Trust

Luton, United Kingdom

Not Yet Recruiting

10

Newcastle Upon Tyne Hospitals NHS Trust

Newcastle, United Kingdom

Actively Recruiting

11

Norfolk and Norwich University Hospitals NHS Foundation Trust

Norwich, United Kingdom

Actively Recruiting

12

Oxford University Hospitals NHS Trust

Oxford, United Kingdom

Actively Recruiting

13

Portsmouth Hospitals University NHS Trust

Portsmouth, United Kingdom

Not Yet Recruiting

Loading map...

Research Team

S

Sameera Sharma, MBBS; MRCS

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

A Phase 2 Open-Label Study of Ifinatamab Deruxtecan in Parti...

Oesophageal Squamous Cell Carcinoma

Actively Recruiting

17 locations

A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alon...

Metastatic Cancer

Actively Recruiting

1 location

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor...

Carcinoma, Hepatocellular

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here